Testing effectiveness (Phase 2)Study completedNCT01658436
What this trial is testing
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Who this might be right for
Pancreatic Neuroendocrine Tumors (pNET)
Novartis Pharmaceuticals 31